Observing that DGK-α and DKG-ζ are exploited by cancer cells to suppress the activity of cytotoxic immunocytes in the tumor microenvironment encourages the idea that DGK-inhibitors might enrich the current cancer immunotherapy armamentarium. This evidence concerns the gene DGKA and neoplasm.